MA71708A - Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1 - Google Patents

Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1

Info

Publication number: MA71708A
Authority: MA; Morocco
Prior art keywords: antibodies; cd3xmuc16; methods; treating cancer; bispecific
Prior art date: 2018-06-21

Application number

MA71708A

Other languages

English (en)

Inventor

Alison CRAWFORD

Original Assignee

Regeneron Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-06-21

Filing date

2019-06-20

Publication date

2025-05-30

2019-06-20 Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.

2025-05-30 Publication of MA71708A publication Critical patent/MA71708A/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Cell Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Mycology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MA71708A 2018-06-21 2019-06-20 Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1 MA71708A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201862688251P	2018-06-21	2018-06-21
EP24176671.6A EP4424712A3 (fr)	2018-06-21	2019-06-20	Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1

Publications (1)

Publication Number	Publication Date
MA71708A true MA71708A (fr)	2025-05-30

Family

ID=67254001

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MA52962A MA52962B1 (fr)	2018-06-21	2019-06-20	Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1
MA71708A MA71708A (fr)	2018-06-21	2019-06-20	Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
MA52962A MA52962B1 (fr)	2018-06-21	2019-06-20	Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1

Country Status (26)

Country	Link
US (1)	US11254752B2 (fr)
EP (2)	EP4424712A3 (fr)
JP (1)	JP7403480B2 (fr)
KR (1)	KR102870971B1 (fr)
CN (1)	CN112312970B (fr)
AU (1)	AU2019290170A1 (fr)
BR (1)	BR112020025476A2 (fr)
CA (1)	CA3103887A1 (fr)
CL (1)	CL2020003256A1 (fr)
DK (1)	DK3810281T3 (fr)
EA (1)	EA202190088A1 (fr)
ES (1)	ES2984972T3 (fr)
FI (1)	FI3810281T3 (fr)
HU (1)	HUE067985T2 (fr)
IL (1)	IL279251B1 (fr)
MA (2)	MA52962B1 (fr)
MX (2)	MX2020013905A (fr)
MY (1)	MY202134A (fr)
PH (1)	PH12020552115A1 (fr)
PL (1)	PL3810281T3 (fr)
PT (1)	PT3810281T (fr)
RS (1)	RS65886B1 (fr)
SG (1)	SG11202012137UA (fr)
TW (2)	TWI890661B (fr)
WO (1)	WO2019246356A1 (fr)
ZA (1)	ZA202007599B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI635098B (zh)	2013-02-01	2018-09-11	再生元醫藥公司	含嵌合恆定區之抗體
US10556952B2 (en)	2015-03-30	2020-02-11	Regeneron Pharmaceuticals, Inc.	Heavy chain constant regions with reduced binding to Fc gamma receptors
TWI784917B (zh)	2015-09-23	2022-11-21	美商再生元醫藥公司	最優化抗ｃｄ３雙特異性抗體及其用途
IL280875B2 (en)	2018-08-31	2024-12-01	Regeneron Pharma	Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
CN116472060A (zh) *	2020-09-02	2023-07-21	健玛保	抗体疗法
SI4284512T1 (sl)	2021-01-28	2025-06-30	Regeneron Pharmaceuticals, Inc.	Sestavki in postopki za zdravljenje sindroma sproščanja citokinov
CN117729938A (zh) *	2021-03-18	2024-03-19	纪念斯隆-凯特琳癌症中心	用于使用利用抗muc16×cd3多特异性抗体和vegf抑制剂的组合疗法治疗妇科癌症的方法
WO2023033022A1 (fr)	2021-08-31	2023-03-09	日本メジフィジックス株式会社	Complexe radioactif d'anticorps déglycosylé et produit pharmaceutique radioactif
IL312813A (en) *	2021-11-24	2024-07-01	Regeneron Pharma	Methods for treating cancer using bispecific antibodies against CD3 and MUC16 and antibodies against CTLA-4
KR20240130137A (ko) *	2022-01-07	2024-08-28	리제너론 파아마슈티컬스, 인크.	이중특이적 항-MUC16 x 항-CD3 항체 단독으로 또는 항-PD-1 항체와의 조합으로 재발성 난소암을 치료하는 방법
EP4464722A4 (fr) *	2022-01-10	2026-03-04	Nanjing Leads Biolabs Co Ltd	Anticorps et son utilisation
CN119031932A (zh) *	2022-03-16	2024-11-26	第一三共株式会社	多特异性分子和免疫检查点抑制剂的组合
US20230357446A1 (en)	2022-04-11	2023-11-09	Regeneron Pharmaceuticals, Inc.	Compositions and methods for universal tumor cell killing
IL322545A (en)	2023-02-17	2025-10-01	Regeneron Pharma	Induced NK cells responding to bispecific CD3/TAA antibodies

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7087411B2 (en)	1999-06-08	2006-08-08	Regeneron Pharmaceuticals, Inc.	Fusion protein capable of binding VEGF
WO2001014557A1 (fr)	1999-08-23	2001-03-01	Dana-Farber Cancer Institute, Inc.	Pd-1, recepteur de b7-4, et son utilisation
CN1753912B (zh)	2002-12-23	2011-11-02	惠氏公司	抗pd-1抗体及其用途
ES2720160T3 (es)	2005-05-09	2019-07-18	Ono Pharmaceutical Co	Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
JP5191537B2 (ja)	2007-06-18	2013-05-08	エム・エス・ディー・オス・ベー・フェー	ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
EP2262837A4 (fr)	2008-03-12	2011-04-06	Merck Sharp & Dohme	Protéines de liaison avec pd-1
RS54233B1 (sr)	2008-08-25	2015-12-31	Amplimmune Inc.	Kompozicije pd-1 antagonista i postupci za njihovu primenu
KR101747103B1 (ko)	2009-06-26	2017-06-14	리제너론 파마슈티칼스 인코포레이티드	천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
JP6240600B2 (ja)	2011-07-24	2017-11-29	キュアテクリミテッド	ヒト化免疫モノクローナル抗体の変異体
TWI635098B (zh)	2013-02-01	2018-09-11	再生元醫藥公司	含嵌合恆定區之抗體
TWI681969B (zh)	2014-01-23	2020-01-11	美商再生元醫藥公司	針對ｐｄ-１的人類抗體
TWI701042B (zh)	2014-03-19	2020-08-11	美商再生元醫藥公司	用於腫瘤治療之方法及抗體組成物
TWI784917B (zh) *	2015-09-23	2022-11-21	美商再生元醫藥公司	最優化抗ｃｄ３雙特異性抗體及其用途
MA44146B1 (fr)	2015-12-22	2023-10-31	Regeneron Pharma	Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer
TWI786044B (zh)	2016-05-13	2022-12-11	美商再生元醫藥公司	藉由投予ｐｄ-１抑制劑治療皮膚癌之方法
HRP20221202T1 (hr) *	2016-09-23	2022-12-09	Regeneron Pharmaceuticals, Inc.	Anti-muc16 (mucin 16) antitijela
PE20240950A1 (es) *	2016-10-14	2024-05-06	Xencor Inc	PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
WO2018099539A1 (fr)	2016-11-29	2018-06-07	Horst Lindhofer	Combinaison d'anticorps multifonctionnels de redirection de lymphocytes (t) avec des modulateurs de point de contrôle immunitaires et leurs utilisations

2019
- 2019-06-19 TW TW108121196A patent/TWI890661B/zh active
- 2019-06-19 TW TW113114645A patent/TW202504917A/zh unknown
- 2019-06-20 US US16/447,067 patent/US11254752B2/en active Active
- 2019-06-20 MA MA52962A patent/MA52962B1/fr unknown
- 2019-06-20 AU AU2019290170A patent/AU2019290170A1/en active Pending
- 2019-06-20 BR BR112020025476-2A patent/BR112020025476A2/pt unknown
- 2019-06-20 KR KR1020217000649A patent/KR102870971B1/ko active Active
- 2019-06-20 PT PT197394729T patent/PT3810281T/pt unknown
- 2019-06-20 EP EP24176671.6A patent/EP4424712A3/fr active Pending
- 2019-06-20 SG SG11202012137UA patent/SG11202012137UA/en unknown
- 2019-06-20 CN CN201980040564.9A patent/CN112312970B/zh active Active
- 2019-06-20 ES ES19739472T patent/ES2984972T3/es active Active
- 2019-06-20 JP JP2020570938A patent/JP7403480B2/ja active Active
- 2019-06-20 MA MA71708A patent/MA71708A/fr unknown
- 2019-06-20 DK DK19739472.9T patent/DK3810281T3/da active
- 2019-06-20 EA EA202190088A patent/EA202190088A1/ru unknown
- 2019-06-20 RS RS20240959A patent/RS65886B1/sr unknown
- 2019-06-20 CA CA3103887A patent/CA3103887A1/fr active Pending
- 2019-06-20 MY MYPI2020006505A patent/MY202134A/en unknown
- 2019-06-20 HU HUE19739472A patent/HUE067985T2/hu unknown
- 2019-06-20 PL PL19739472.9T patent/PL3810281T3/pl unknown
- 2019-06-20 MX MX2020013905A patent/MX2020013905A/es unknown
- 2019-06-20 EP EP19739472.9A patent/EP3810281B1/fr active Active
- 2019-06-20 FI FIEP19739472.9T patent/FI3810281T3/fi active
- 2019-06-20 WO PCT/US2019/038163 patent/WO2019246356A1/fr not_active Ceased
2020
- 2020-12-07 ZA ZA2020/07599A patent/ZA202007599B/en unknown
- 2020-12-07 IL IL279251A patent/IL279251B1/en unknown
- 2020-12-10 PH PH12020552115A patent/PH12020552115A1/en unknown
- 2020-12-16 CL CL2020003256A patent/CL2020003256A1/es unknown
- 2020-12-16 MX MX2025008444A patent/MX2025008444A/es unknown

Also Published As

Publication number	Publication date
CN112312970B (zh)	2025-05-23
EP4424712A3 (fr)	2024-11-13
SG11202012137UA (en)	2021-01-28
US11254752B2 (en)	2022-02-22
MY202134A (en)	2024-04-05
ES2984972T3 (es)	2024-10-31
IL279251B1 (en)	2025-11-01
KR20210023981A (ko)	2021-03-04
EP3810281B1 (fr)	2024-07-24
RS65886B1 (sr)	2024-09-30
FI3810281T3 (fi)	2024-08-14
IL279251A (en)	2021-01-31
TW202005985A (zh)	2020-02-01
WO2019246356A1 (fr)	2019-12-26
US20190389966A1 (en)	2019-12-26
KR102870971B1 (ko)	2025-10-16
MA52962A (fr)	2021-04-28
PL3810281T3 (pl)	2024-11-04
MA52962B1 (fr)	2024-10-31
EP3810281A1 (fr)	2021-04-28
AU2019290170A1 (en)	2021-01-07
MX2020013905A (es)	2021-03-09
HUE067985T2 (hu)	2024-12-28
BR112020025476A2 (pt)	2021-03-16
EP4424712A2 (fr)	2024-09-04
PT3810281T (pt)	2024-08-02
TW202504917A (zh)	2025-02-01
PH12020552115A1 (en)	2021-08-02
TWI890661B (zh)	2025-07-21
DK3810281T3 (da)	2024-08-19
JP7403480B2 (ja)	2023-12-22
CA3103887A1 (fr)	2019-12-26
CL2020003256A1 (es)	2021-04-30
ZA202007599B (en)	2025-02-26
EA202190088A1 (ru)	2021-03-22
JP2021528423A (ja)	2021-10-21
CN112312970A (zh)	2021-02-02
MX2025008444A (es)	2025-08-01

Publication	Publication Date	Title
MA71708A (fr)	2025-05-30	Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1
EP3752193A4 (fr)	2022-02-23	Méthodes de traitement du cancer avec des anticorps anti pd-1 et des anticorps anti ctla4
MA52789A (fr)	2021-04-14	Méthodes de traitement du cancer avec des anticorps anti-pd-1
MA51631A (fr)	2020-11-18	Anticorps anti-pd1 et méthodes de traitement
MA44146A (fr)	2018-10-31	Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer
CL2018000728A1 (es)	2019-04-26	Anticuerpos anti-cd19 humano humanizados y métodos de utilización
EP3826667A4 (fr)	2022-07-27	Anticorps contre claudin 6 et procédés de traitement du cancer
MA47604A (fr)	2020-01-01	Anticorps anti-pd-1 pour le traitement du cancer du poumon
EP3634442A4 (fr)	2021-05-26	Méthodes de traitement et de prévention de maladies
EP3573658A4 (fr)	2021-07-21	Anticorps anti-tnf, compositions et méthodes pour le traitement du rhumatisme psoriasique actif
MA53506A (fr)	2021-07-07	Méthodes de traitement du cancer avec des inhibiteurs de pd-l1 à petites molécules
EP3370707A4 (fr)	2019-10-09	Procédés de traitement de cancer utilisant des compositions d'anticorps et des protéines porteuses avec un prétraitement d'anticorps
IL269718A (en)	2019-11-28	Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
EP3426777A4 (fr)	2019-09-11	Vecteurs de combinaison et méthodes de traitement du cancer
MA55717A (fr)	2022-02-23	Méthodes de traitement du cancer de la prostate avec un anticorps anti-psma/cd3
EP3681498A4 (fr)	2021-06-02	Méthodes et compositions pour le traitement du cancer
EP3688023A4 (fr)	2021-06-30	Méthodes et compositions pour le traitement du cancer
EP3638293A4 (fr)	2021-03-10	Méthodes et compositions pour le traitement du cancer
EP3968987A4 (fr)	2022-10-26	Méthodes et substances pour le traitement du cancer
EP3873205A4 (fr)	2022-05-11	Substances et méthodes pour le traitement du cancer
EP3870104A4 (fr)	2022-11-23	Méthodes et substances pour le traitement du cancer
EP3806845A4 (fr)	2022-04-06	Composition de cannabinoïdes et méthodes de traitement utilisant cette dernière
EP3773625A4 (fr)	2021-05-19	Méthodes et matériels pour le traitement du cancer
MA48751A (fr)	2020-04-08	Paradigme de traitement pour un traitement combiné d'anticorps anti-cd19 et de venetoclax
EP4061846A4 (fr)	2023-12-20	Procédés de traitement du cancer utilisant des anticorps anti-ox40 en combinaison avec des anticorps anti-tigit